

dADDITIONAL FILE_1

Muñoz-Galván et al., “Downregulation of *MYPT1* increases tumor resistance in ovarian cancers by targeting the Hippo pathway and increasing the stemness”

Table S1. Reagents used in this work.

Antibody	Dilution	Reference
anti-MYPT1 (D6C1)	1:1000	Cell Signaling #8574S
anti-NF2 [AF1G4]	1:1000	Abcam #ab88957
anti-NF2/Merlin (phosphoS518)	1:1000	Abcam #ab2478
phospho-MST1/2 (T180/T183)	1:200	Abcam #ab76323
phospho-LAST1 (T1079)	1:1000	Cell Signaling #8654S
LAST1	1:1000	Cell Signaling #3477S
YAP	1:1000	Cell Signaling #4912
TAZ	1:1000	Abcam #ab84927
XIAP (H-202)	1:500	SantaCruz#sc-11426
hnRNP C1/C2 (4F4)	1:500	SantaCruz#sc-32308
phospho-YAP (Ser127)	1:1000	Cell Signaling #13008
mAb anti- α -tubulin	1:5000	Sigma 9026
peroxidase-labeled rabbit anti-mouse	1:10000	Amersham
peroxidase-labeled goat anti-rabbit	1:10000	Abcam #6721
CD10-FITC		Myltenyi
CD19-APC		Myltenyi
CD24-PE		Myltenyi
CD34-PE		Myltenyi
CD44-APC		Myltenyi
CD117-APC		Myltenyi
CD133-PE		Myltenyi
CD184-PE		Myltenyi
Probe		Reference
MYPT1		ThermoFisher#Hs01552899
NANOG		ThermoFisher#Hs04260366
BMI-1		ThermoFisher#Hs00995536
SOX2		ThermoFisher#Hs01053049
OCT4		ThermoFisher#Hs00999632
BIRC5		ThermoFisher#Hs04194392
CTGF		ThermoFisher#Hs01026927
FGF1		ThermoFisher#Hs01092738
GLI2		ThermoFisher#Hs01119974
EPCAM		ThermoFisher#Hs00901885
CD44		ThermoFisher#Hs01075864
MIR30B		ThermoFisher#Hs4427975
GAPDH		ThermoFisher#Hs03929097

Table S2: Characteristics of patient public databases used in this study

	GSE40595 N=77	GSE38666 N=45	GSE14764 N=80
Age (years)	0-76	41-78	36-81
Stage (FIGO 2014) • I • II • III • IV • n.a.	High grade	0 7 (15.5%) 18 (40%) 0 20 (44.5%)	7 (8.8%) 1 (1.3%) 67 (83.8%) 5 (6.3%)
Histology • Serous carcinoma • Non serous carcinoma • undiff	77(100%) 0 0	45 (100%) 0 0	67 (83.8%) 10 (12.5%) 3 (3.8%)

Table S3. CSC markers in OVCAR8 and SKOV3 ovarian tumor cell lines

CSC marker (%)	OVCAR8		SKOV3	
	Ev	<i>shMYPT1</i>	Ev	<i>shMYPT1</i>
CD10	0.2 ± 0.1	0.3 ± 0.1	0.3 ± 0.1	0.6 ± 0.1
CD19	0.3 ± 0.1	0.4 ± 0.1	0.2 ± 0.1	6.5 ± 0.2
CD24	≥ 99%	≥ 99%	≥ 99%	≥ 99%
CD34	0	0	0	0
CD44	≥ 99%	≥ 99%	≥ 99%	≥ 99%
CD117	0.3 ± 0.15	0.4 ± 0.1	0.3 ± 0.1	0.5 ± 0.1
CD133	0.3 ± 0.1	0.4 ± 0.1	0.2 ± 0.1	0.5 ± 0.2
CD184	8.8 ± 0.5	8.6 ± 0.4	0.2 ± 0.1	0.2 ± 0.1

Table S4: Patient Cohort characteristics

	Sensitive N=9 (40%)	Resistant N=13(60%)
Age (years)		
• Mean (Rank)	62,0 (34-70)	51,0 (40-67)
ECOG		
• 0	7 (77,8%)	5 (38,5%)
• 1	1 (11,1%)	6 (46,2%)
• 2	1 (11,1%)	2 (15,4%)
Stage (FIGO 2014)		
• IA	1 (11,1%)	1 (7,7%)
• IC	1 (11,1%)	1 (7,7%)
• IIB	1 (11,1%)	0
• IIIB	1 (11,1%)	1 (7,7%)
• IIIC	4 (44,4%)	8 (61,5%)
• IVA	1 (11,1%)	0
• IVB	0	2 (15,4%)
Ca 125 (U/ml)		
• Diagnosis: Median (Rank)	194 (31,6-21957)	332 (38-3892)
• After treatment: Median (Rank)	11 (6,5-1400)	76,1 (15,5-1862)
Adjuvant Chemotherapy		
• No	6 (66,7%)	7 (53,8%)
• Yes	3 (33,3%)	6 (46,2%)
Treatment		
• Carbo + Paclitaxel	6 (68%)	12 (92%)
• Carbo + Paclitaxel + beva	3 (32%)	0
• Carbo monoterapia	0	1 (8%)
Surgery		
• R0	1 (11,1%)	2 (15,4%)
• R1	2 (22,2%)	2 (15,4%)
• Biopsies	0	2 (15,4%)
• No (incluyen pacientes con cirugía primaria)	6 (66,7%)	7 (53,8%)
Mejor respuesta a QT adyuvante o 1ª línea		
• RC	6 (66,7%)	4 (30,8%)
• RP	3 (33,3%)	2 (15,4%)
• EE	0	2 (15,4%)
• PE	0	5 (38,5%)
Treatment after 1st line		
• Bevacizumab	3 (33,3%)	0
• Others	0	0
• No	6 (66,7%)	13 (100%)
Progression disease after treatment		
• yes	6 (66,7%)	13 (100%)
• No	3 (33,3%)	0
Platinum free interval (moths)		
• Mean (Rank)	19 (7-33)	1 (0-5)
More than 2 lines of treatment		
• yes	4 (44,4%)	4 (30,8%)
• No	5 (55,6%)	9 (69,12%)
Status patient in last visit		
• Live without disease	2 (22,2%)	0
• Live with disease	4 (44,4%)	2 (15,4%)
• Death (all due to disease progression)	3 (33,3%)	11 (84,6%)
Location primary tumor		
• Right ovary	2 (22,2%)	2 (15,4%)
• Left ovary	2 (22,2%)	4 (30,8%)
• Bilateral	5 (55,6%)	5 (38,5%)
• Peritoneal	0	2 (15,4%)
Differentiation		
• Moderately	1 (11,1%)	1 (7,7%)

• Poor • nd	7 (77,8%) 1 (11,1%)	11 (84,6%) 1 (7,7%)
Histology • Serous carcinoma • Clear cell carcinoma • Others	7 (77,8%) 2 (22,2%) 0	8 (61,5%) 3 (23,1%) 2 (15,4%)
Lymphovascular infiltration • No • Yes • nd	1 (11,1%) 2 (22,2%) 6 (66,7%)	1 (7,7%) 1 (7,7%) 11 (84,6%)
BRCA Mutation • No • Yes • nd	4 (44,4%) 2 (22,2%) 3 (33,3%)	6 (46,2%) 0 7 (53,8%)